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Abstract:
Background: Early detection and removal of colorectal cancer (CRC) and 
advanced adenomas (AA) decreases incidence and mortality. 
Objective: We aimed to evaluate potential of faecal volatile organic 
compounds (VOC) for colorectal adenomas detection and follow-up using 
advanced electronic nose technology. 
Methods: This was a prospective multi-centre case-control cohort 
including two district hospitals and one tertiary referral hospital. Patients 
undergoing colonoscopy were instructed to collect a faecal sample prior 
to bowel cleansing and were included when CRC, AA, large adenomas 
(LA; 0.5-1.0cm), small adenomas (SA; 0.1-0.5cm) or no endoscopic 
abnormalities (healthy controls; HC) were observed. Patients undergoing 
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polypectomy and HC were asked for a second sample after three 
months. Faecal VOCs were measured with gas chromatography-ion 
mobility spectrometry. Random Forest, Support Vector Machine, 
Gaussian Process and Neural Net classification were used to evaluate 
accuracy. 
Results: In total, 14 CRC, 64 AA, 69 LA, 127 SA and 227 HC were 
included. Second sample was collected by 32 polypectomy patients and 
32 HC. Faecal VOCs discriminated CRC and adenomas from HC 
(AUC(95%): CRC vs HC 0.96(0.89-1); AA vs HC 0.96(0.93-1); LA vs HC 
0.96(0.92-0.99); SA vs HC 0.96(0.94-0.99)). There were no significant 
differences between CRC and adenoma groups. Patients with adenomas 
and HC were discriminated prior to polypectomy, whereas three months 
after polypectomy VOC profiles were similar (T0 adenoma vs HC 
0.98(0.95-1); T1 adenoma vs HC 0.55(0.40-0.69)). 
Conclusion: Faecal VOC profiles may be useful for early CRC and 
adenoma detection, and timing of polyp surveillance as polypectomy led 
to a normalization of VOC profile. 
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Background: Early detection and removal of colorectal cancer (CRC) and advanced 
adenomas (AA) decreases incidence and mortality.
Objective: We aimed to evaluate potential of faecal volatile organic compounds 
(VOC) for colorectal adenomas detection and follow-up using advanced electronic 
nose technology.
Methods: This was a prospective multi-centre case-control cohort including two 
district hospitals and one tertiary referral hospital. Patients undergoing colonoscopy 
were instructed to collect a faecal sample prior to bowel cleansing and were included 
when CRC, AA, large adenomas (LA; 0.5-1.0cm), small adenomas (SA; 0.1-0.5cm) 
or no endoscopic abnormalities (healthy controls; HC) were observed. Patients 
undergoing polypectomy and HC were asked for a second sample after three 
months. Faecal VOCs were measured with gas chromatography-ion mobility 
spectrometry. Random Forest, Support Vector Machine, Gaussian Process and 
Neural Net classification were used to evaluate accuracy. 
Results: In total, 14 CRC, 64 AA, 69 LA, 127 SA and 227 HC were included. Second 
sample was collected by 32 polypectomy patients and 32 HC. Faecal VOCs 
discriminated CRC and adenomas from HC (AUC(95%): CRC vs HC 0.96(0.89-1); 
AA vs HC 0.96(0.93-1); LA vs HC 0.96(0.92-0.99); SA vs HC 0.96(0.94-0.99)). There 
were no significant differences between CRC and adenoma groups. Patients with 
adenomas and HC were discriminated prior to polypectomy, whereas three months 
after polypectomy VOC profiles were similar (T0 adenoma vs HC 0.98(0.95-1); T1 
adenoma vs HC 0.55(0.40-0.69)). 
Conclusion: Faecal VOC profiles may be useful for early CRC and adenoma 
detection, and timing of polyp surveillance as polypectomy led to a normalization of 
VOC profile. 
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 Fecal volatile organic compounds have previously been shown to hold 
potential for the detection of colorectal cancer
What is new?
 Faecal volatile organic compounds hold potential to detect polyps, as well as 
advanced adenomas and colorectal cancer.
 There are no differences in fecal scent profiles between the different types of 
adenomas and colorectal cancer
 Prior to polypectomy, there is a difference in scent profile between patients 
with polyps and healthy controls, whereas after polypectomy these profiles are 
similar. 
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Colorectal cancer (CRC) is one of the three malignancies with the highest incidence 
in the industrialized world, with a 5-year survival rate of 64.4% and 66.6% for colon 
and rectum cancer, respectively1. Majority of CRC originates from dysplastic 
adenomatous polyps, so-called advanced adenomas (AA)2. Early detection and 
removal of these precancerous polyps is essential for improvement of CRC course 
and prognosis, illustrated by a gradually decrease of survival rates with increasing 
cancer stage3. Faecal immunochemical test (FIT) is widely used for population-based 
screening but lacks sensitivity, indicated by the missed diagnosis of CRC in 1-47% 
and AA in 43-61% of the tests4. In addition, specificity is suboptimal, as 
approximately 7% of the performed tests provide false-positive results leading to the 
performance of unneeded colonoscopies. This emphasizes the need for improvement 
of CRC/AA bowel screening tools. 
Endoscopic assessment is advised after FIT positivity, but also remains key for 
surveillance after removal of polyps (polypectomy) and following CRC treatment3, as 
these patients remain at increased risk for development or recurrence of dysplastic 
lesions. Thus far, no non-invasive biomarkers have been validated for this purpose.
Analysis of the faecal volatolome is a novel approach within the field of biomarker 
exploration. The faecal volatolome consists of volatile organic compounds (VOCs), 
which are carbon-bound molecules. Composition of the faecal volatolome is 
considered to reflect metabolic processes in the human body, like inflammation, 
necrosis, change in dietary intake, gut microbial dysbiosis and cancer growth5,6. 
Several studies have focused on the application of the faecal volatolome as a 
biomarker for detection of CRC and AA, with promising results. However, none of the 
available studies have included patients with (low-risk) adenomas to explore the 
specificity of VOC analysis. Aim of this study was to assess the potential of faecal 
VOC as non-invasive biomarker to detect colonic neoplasia and precursor lesions. In 
addition, we aimed to explore its potential for secondary non-invasive surveillance 
following polypectomy.
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This multi-centre prospective case-control study was performed between February 
2015 and November 2017 at outpatient clinics of Gastroenterology and Hepatology 
departments in one tertiary referral hospital (Amsterdam UMC, location VUmc) and 
two district hospitals (OLVG West, Amsterdam and Spaarne Gasthuis, Hoofddorp 
and Haarlem), all located in The Netherlands. This study was approved by the 
Medical Ethical Review Committee (METc) of Amsterdam UMC (2014.404), and by 
local METcs of OLVG West and Spaarne Gasthuis. Written informed consent was 
obtained from all participants.
Study participants and sample collection
Detection of colorectal adenomas and cancer
All patients aged  ≥18 years with a scheduled colonoscopy were asked to participate 
in this study, irrespective of endoscopy indication. Patients were divided into five 
subgroups based on observations during endoscopy, combined with histology reports 
in case biopsies or polypectomies were performed: (a) CRC, histologically confirmed 
carcinoma of the colon or rectum; (b) Advanced adenoma (AA), according to the 
European Society of Gastrointestinal Endoscopy (ESGE), that is, characterized by 
polyps ≥1cm in diameter, or with villous histology, or high grade dysplasia; (c) Large 
adenoma (LA), adenomas sized 0.5-1.0cm in diameter without villous histology or 
high grade dysplasia; (d) Small adenoma (SA), adenomas sized <0.5cm in diameter 
without villous histology or high grade dysplasia; (e) Healthy controls (HC), 
characterized by no abnormalities observed during endoscopy (excluding small anal 
fibroma, haemorrhoids and/or diverticula), and in case of mucosal biopsies, no 
histopathological abnormalities7. Participants were asked to collect a faecal sample 
(Stuhlgefäß 10ml, Frickenhausen, Germany) prior to bowel preparation, store the 
sample in their own freezer at home within one hour following bowel movement and 
bring it to the hospital on the day of their endoscopic assessment. Samples were 
stored at -24°C directly upon arrival at the hospital. Participants were asked to 
complete a questionnaire on the day of sample collection, which included items on 
age, gender, body mass index (BMI), smoking habits, comorbidity and medication 
use. Exclusion criteria were presence of a known underlying gastrointestinal disease, 
incomplete endoscopic assessment due to various reasons (e.g. inadequate bowel 
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cleansing, pain) and/or inability to collect or store sufficient faecal sample mass to 
perform VOC analysis. 
Monitoring of patients post-polypectomy
Between May and November 2017, patients who underwent a successful 
polypectomy during endoscopy were asked to participate in the follow-up part of this 
study. Participants were excluded from this group in case of incomplete removal of 
polyps. Remaining polypectomy patients were randomly matched to HC in a 1:1 ratio. 
All patients included in the second part of this study were asked to collect a follow-up 
faecal sample and complete a second questionnaire (same procedure as the first 
sample and questionnaire). These samples and questionnaires were collected by 
one of the researchers and transported to the hospital on dry ice where they were 
stored at -24°C upon arrival.
Endoscopic and histologic evaluation
Endoscopy reports and histologic outcome of mucosal biopsies and/or polypectomy 
were checked using electronic patient files. These outcomes were used as standard 
reference for localization and total number of removed adenomas in this study. 
Endoscopies were either performed or supervised by trained gastroenterologists. 
Histopathological reports were used as the standard reference for size, differentiation 
grade (e.g. hyperplasia, dysplasia), villous histology and type of CRC in this study. 
Mucosal biopsies were noted as sized 0.2 cm. The presence of sessile and/or 
serrated characteristics was noted for all non-advanced adenomas. When multiple 
polyps were present, classification was based on the most advanced or largest 
lesion.
Sample preparation and faecal volatile organic compound analysis
One frozen subsample of 500 mg per participant was weighted and transferred into 
glass vials (20ml headspace vial, Thames Restek, Saunderton, UK). Samples were 
transported to the University of Warwick (Coventry, UK) for faecal VOC analysis. Gas 
chromatography-ion mobility spectrometer (GC-IMS, FlavourSpec®, G.A.S., 
Dortmund, Germany) was used to measure the faecal VOC patterns. In GC-IMS, 
analytes are pre-separated by retention time in a GC column (SE54 column) before 
entering the ion mobility spectrometer (IMS). Within the IMS system, soft chemical-
ionization is performed using a low-radiation tritium (H3) source, subsequently 
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creating reactant ions with injected gas. Ionized VOCs travel against flow of an inert 
drift gas. Drift time of each substance is determined by ions mass and geometrical 
structure due to interactions with the drift gas. In general, the larger the molecule, the 
more it loses its momentum and thus, the longer it takes to travel along the tube. 
Resulting ion current is measured as a function of time8. Prior to analysis, the 
samples were heated to 80°C for 8 minutes. After this, GC was performed at 40°C 
using nitrogen 99∙9% (3∙5 bar) as carrier gas and IMS was performed at 45°C using 
nitrogen 99∙9% as drift gas. Flow rates were set at 150ml/min (0∙364 kPa) (IMS), and 
20 ml/minute (34,175 kPa) for 6 minutes (GC). A schematic overview of the setup is 
depicted in Figure 1.
Statistical analysis
Using IBM SPSS Statistics (version 22), demographic data of each group were 
calculated and compared. One way ANOVA or Kruskall Wallis tests were used to 
compute differences in baseline d mographics between groups. For the secondary 
part of this study, t-tests, Fisher’s exact test, chi-square and Mann-Whitney U tests 
were used to compute differences between groups. Raw GC-IMS data were pre-
processed to crop areas that contained chemical information. A threshold was 
applied to remove background noise. Then, a correction for instrumental 
disturbances was performed by baseline correction, where reactive ion peaks were 
aligned on all samples. Data were split into three sets, 70% for training and validation 
and 30% as a test set. Wilcoxon rank-sum test was used to find the 20, 50 and 100 
most discriminatory features and subsequently Sparse Logistic Regression, Random 
Forest, Gaussian Process, Support Vector Machine and Neural Net classification 
were used to provide statistical results. In the case of small subgroups of interest, 
subsets of HC were chosen randomly to avoid skewed analyses. 
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In total, 1039 patients collected a faecal sample prior to colonoscopy of which 
samples from 14 CRC patients, 64 AA, 69 LA and 127 SA were included in this 
study. 227 HC were included as they did not have any mucosal abnormalities during 
endoscopy. Baseline demographics of all study participants are depicted in Table 1. 
Age differed significantly between groups (p<0.001), with HC displaying the lowest 
mean age (60 ± 11.8) and AA the highest (68.8 ± 6.7). Gender differed significantly 
between HC, SA, LA and AA (p<0.0001) but not between HC and CRC or any of the 
adenoma groups. There were no significant differences in BMI, smoking status and 
use of antibiotics between groups. 
For the follow-up part of this study, all 32 patients undergoing a complete 
polypectomy and 32 HC subjects were included and collected a second fecal sample 
three months after endoscopy. Baseline demographics of the follow-up study are 
given in Table 2. There were no significant differences in BMI, smoking status and 
use of AB three months prior to sample collected. Gender and age did differ 
significantly between groups (p<0.014, p<0.001, respectively).
Faecal volatile organic compound analysis
Results of VOC analyses by means of GC-IMS are shown in Table 3. Results from 
the Random Forest classifier based on the 20 most discriminative features are 
presented. Data generated based on all five classifiers using the 20, 50 and 100 
most discriminative features are given in Supplemental Table 1-3. 
Detection of colorectal cancer, advanced adenomas and non-advanced adenomas
Based on faecal VOC profiles, CRC was discriminated from HC with high diagnostic 
accuracy (AUC ± 95%CI: 0∙96(0∙89 – 1)(Table 3, Supplementary table 1-3). Likewise, 
high diagnostic accuracy was observed for discrimination of AA, LA and SA when 
compared to HC (AA 0∙96(0∙93 –1); LA 0∙96(0∙92 – 0∙99); SA 0∙96(0∙94-0∙99))(Table 
3, Supplementary tables 1-3). There were no significant differences between any of 
the CRC, AA, LA and SA groups based on faecal VOCs (Table 3, Supplementary 
table 1-3). Receiver operator characteristic (ROC) curves are constructed in Figure 2. 
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Faecal volatile organic compounds for surveillance after polypectomy
Faecal VOC profiles of patients with adenomas differed significantly from HC before 
polyp removal (AUC ± 95%CI: 0∙98(0∙95-1)). Remarkably, there was no difference 
between the faecal VOC profiles of patients who underwent a polypectomy and HC 
three months after endoscopic intervention (AUC ± 95%CI: 0∙55(0∙40-0∙66)). There 
was a highly significant difference in the profiles of patients with adenomas before 
and after polypectomy, whereas no significant differences were present in faecal 
VOC profiles of HC before and three months after endoscopy (T0 vs T1 polyps 
0∙94(0∙88-1); T0 vs T1 HC 0∙58(0∙44-0∙73)). ROC-curves for the follow-up study are 
depicted in Figure 3. 
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We observed high diagnostic accuracies for faecal VOC-based differentiation 
between CRC and HC and between adenomas and HC. Faecal VOC profiles of 
patients with adenomas converted towards those of HC after polypectomy. VOC 
profiles of CRC could not be discriminated from different adenoma types. These 
results demonstrate the potential of faecal VOC analysis for both colonic neoplasia 
screening and surveillance.
This is the first study to assess faecal VOC profiles for CRC and AA detection, which 
included patients with non-advanced adenomas as unique control groups. No 
previous studies have been performed on the potential of focal VOC profiles for 
surveillance after polypectomy. Surveillance of patients after polypectomy using FIT 
has been subject of a previous study comparing stool haemoglobin levels with 
colonoscopy outcomes9. A total of 5225 participants completed a first FIT one year 
after polypectomy, demonstrating sensitivity and specificity values of 27∙6% and 
94∙1% at 40 µg/g, and 51∙7% and 86∙2% at 10 µg/g for CRC, respectively. For AA, 
sensitivity and specificity values were 17∙0% and 95∙1% for 40 µg/g and 33∙0% and 
88∙0% for 10 µg/g, respectively. Replacing colonoscopy with FIT would reduce 
colonoscopies by 71%, but would lead 30-40% missed CRC cases and 40-70% 
missed AA cases. Observed discriminative accuracies for CRC and AA detection 
based on faecal VOC analysis exceed these reported accuracies4,10. In addition, 
accuracy to distinguish patients with adenomas from HC was high prior to 
polypectomy, whereas intra-individual profiles changed to physiological state three 
months following polypectomy, indicating the potential of faecal VOCs as biomarker 
for timing of polyp surveillance, and tight control in high risk populations (e.g. Lynch 
syndrome). 
Few studies have demonstrated the potential to discriminate CRC and AA from HC 
based on faecal VOC analysis. Current study outcomes are in line with this literature. 
However, reliable comparison with other studies is restricted due to the small number 
of included subjects, lack of knowledge on VOC profiles of AA and non-advanced 
adenomas, and the use of various different techniques and sampling protocols. Four 
previous studies have focused on detection of CRC using the analytical platform gas 
chromatography—mass spectrometry (GC-MS), which is considered the gold 
standard for the detection of specific metabolites 11-14. In the most recent publication, 
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a group of adenomatous polyps patients (n=56) was included in addition to CRC 
(n=21) and no neoplasia as HC (n=60). Multiple differences in metabolite levels were 
found. Highest diagnostic accuracy was found for the combination of Propan-2-ol and 
3-methylbutanioc acid discriminating CRC samples from polyps and HC (AUC 0.82). 
These differences specifically provided discrimination between CRC patients and 
other groups, whereas in the current study, VOC profiles differed between CRC and 
adenoma groups compared to HC. Possible explanations for this are the differences 
in faecal VOC analysis technique, and in inclusion criteria per subgroup. In the 
publication by Bond et. al., polyp characteristics are not reported, which hampers 
reliable comparison to our study groups. All other studies using GC-MS reported 
relatively small groups of subjects, ranging from n=9-26 CRC and n=10-60 HC. There 
were interesting similarities in study outcomes (e.g. increased levels of amino acids 
and short-chain fatty acids and decreased levels of polyhydric alcohols and bile acid), 
though, none of these metabolite levels were consequently altered. In one previous 
publication, VOC profiles of 40 CRC, 60 AA and 57 endoscopy controlled HC were 
compared using pattern-recognition (eNose, Cyranose 320 ®)15. Based on faecal 
VOC patterns, CRC and AA were discriminated from HC with sensitivity of 85% and 
62%, and specificity of 87% and 86%, respectively. These test characteristics were 
below characteristics found in the current study, however, using the Cyranose 320®, 
subgroups of CRC and AA were discriminated with moderate accuracy (sensitivity 
75% and specificity 73%). A possibility for this apparent discrepancy is the number of 
CRC patients included in the study by de Meij et al., increasing power to find 
differences between groups. Another possibility is the instrumental difference 
between the Cyranose 320® and the GC-IMS system. The Cyranose 320® uses an 
array of nanocomposite sensors, whereas the GC-IMS system is using drift time. 
Although GC-IMS is more sensitive and repeatable, it cannot measure molecules 
with low proton affinities. Should differentiation between CRC and AA be based on 
these type of molecules they could not have been detected in the current study.
Alterations in faecal VOC patterns represent metabolic shifts that may be explained 
by various mechanisms (e.g. alterations in dietary intake, microbial dysbiosis, 
inflammatory processes, cancer degeneration). In a recent study, metabolic waste 
was retrieved from benign cells, colon cancer cells and breast cancer cells that were 
grown in vitro. It was observed that dogs were able to differentiate cancer cells from 
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benign cells, but not the cell waste of breast from colon cancer, implying that both 
cancers phenotypes seem to share a common smell print16. This may also apply for 
different phenotypes of adenomas; adenoma and eventually CRC degeneration are 
possibly based on a shared (metabolic) pathway, explaining the similarities in VOC 
patterns observed in the current study. Apart from excretion of metabolic end-
products, our findings may be explained by the presence of intestinal dysbiosis. 
Faecal microbiota has important function in protection against invading pathogens 
and strong evidence exists for the association between microbial dysbiosis and 
polyp-associated tissue and colonic neoplasia17. Causality remains unclear; it is 
unknown whether this phenomenon is triggered or maintained by carcinogenesis. 
Intriguingly, in the present study it was found that faecal VOC profiles of patients 
three months after polypectomy were altered to normalcy following this intervention, 
suggesting that the alleged faecal microbial dysbiosis returns to physiological state 
after polyp removal. 
Design of this large, multi-centre prospective cohort contributed to generalizability of 
the outcomes. Bias by colonic abnormalities was avoided by including an endoscopy 
controlled HC subgroup. This study also had some limitations. Most importantly, CRC 
subgroup was relatively small which may have contributed to the inability to 
discriminate CRC and adenoma profiles. In addition, even though most variables 
expected to influence faecal VOC profiles were evenly present in the subgroups (i.e. 
smoking status, BMI and use of antibiotics), gender and age did differ between groups. 
Data on the influence of age and gender on faecal VOC profiles are lacking and we 
were therefore not able to exclude this possible bias. 
Future research aimed at creating a disease-specific faecal VOC algorithms for CRC 
and adenoma detection may focus either on pattern-recognition or on metabolite 
specific analytical platforms. The use of pattern-recognition may be favourable for this 
purpose since this allows for fast, easy-to-perform, high-throughput and low-cost 
analyses, underlining its suitability for application in clinical practice. Using machine 
learning, algorithms may be built for the detection of CRC and its precursor lesions, 
which improve continuously with increasing numbers of samples measured. Once the 
algorithm reaches satisfactory accuracy, the device may be implemented not only for 
population based screening but also for intra-individual surveillance after polyp or CRC 
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removal. For surveillance, the device should be validated coupled to endoscopy 
outcomes in the surveillance program. Last, our data have raised the hypothesis that 
faecal VOCs associated with CRC and AA may be a consequence rather than the 
cause of adenoma presence. It would be interesting from a pathophysiological and 
therapeutic point of view to unravel the underlying entities causing the faecal VOC 
differences pre- and post-polypectomy. 
In conclusion, because of its high sensitivity, this study highlights the potential faecal 
VOC analysis for population based screening. Additionally, intra-individual faecal VOC 
profiles of patients with adenomas altered towards a physiological state following 
polypectomy, emphasizing its potential for intra-individual surveillance and timing of 
endoscopy. 
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Age (mean, ± s∙d∙) 66∙6 ± 8∙7 68∙8 ± 6∙7 68∙7 ± 7∙2 63∙7 ± 10∙0 60 ± 11∙8
Gender, f (n, [%]) 6 [42∙9] 17 [26∙3] 21 [30∙4] 44 [34∙6] 129 [56∙8]
BMI* (mean, ± s∙d∙) 25∙9 ± 5∙3 27∙0 ± 4∙1 26∙6 ± 3∙9 27∙3 ± 6∙5 26∙6 ± 7∙0
ABx 3 months prior to 
inclusion (n, [%])
0 [0] 6 [9∙4] 3 [4∙3] 21 [16∙5] 31 [13∙7]
Smoking Status (n, [%])
Active 2 [14∙3] 9 [14∙1] 15 [21∙7] 23 [18∙1] 37 [16∙3]
Quit 10 [71∙4] 37 [57∙8] 36 [52∙2] 64 [50∙4] 92 [40∙5]
Never 2 [14∙3] 18 [28∙1] 17 [24∙6] 40 [31∙5] 98 [43∙2]
Size largest adenoma 
(mean, ± s∙d∙)
0∙7 ± 0∙63 1∙4 ± 0∙64 0∙7 ± 0∙26 0∙4 ± 0∙32 NA
Localization of Largest adenoma† (n, [%])
Caecum 0 [0] 4 [6∙3] 7 [10∙1] 12 [9∙4] NA
Colon Ascendens 1 [7∙1] 8 [12∙5] 12 [17∙4] 32 [25∙2] NA
Flexura Hepatica 1 [7∙1] 2 [3∙1] 0 [0] 1 [0∙8] NA
Colon Transversum 0 [0] 3 [4∙7] 15 [21∙7] 18 [14∙2] NA
Flexura Lienalis 0 [0] 1 [1∙6] 0 [0] 1 [0∙8] NA
Colon Descendens 1 [7∙1] 4 [6∙3] 6 [8∙7] 9 [7∙1] NA
Sigmoid 5 [35∙7] 30 [46∙9] 19 [27∙5] 24 [18∙9] NA
Rectosigmoid 2 [14∙3] 3 [4∙7] 1 [1∙4] 4 [3∙1] NA
Rectum 2 [14∙3] 6 [9∙4] 6 [8∙7] 14 [11∙0] NA
Terminal ileum 1 [7∙1] 0 [0] 0 [0] 1 [0∙8] NA
CRC type (n, [%])
Adenocarcinoma 12 NA NA NA NA
Neuroendocrine 2 NA NA NA NA
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AA characteristics (largest adenoma) (n, [%])
≥ 10 mm NA 54 [84∙4] NA NA NA
Villous histology NA 31 [48∙4] NA NA NA
HGD NA 6 [9∙4] NA NA NA
Polyp characteristics (largest adenoma) (n, [%])
No dysplasia NA 1 [1∙6] 9 [13∙0] 9 [7∙1] NA
Hyperplasia NA 2 [3∙1] 4 [5∙8] 14 [11∙0] NA
LGD NA 55 [85∙9] 55 [79∙7] 100 [78∙7] NA
Sessile/serrated NA NA 8 [11∙6] 10 [7∙9] NA
Total number adenomas removed (n, [%])
1 6 [42∙8] 11 [17∙2] 18 [26∙1] 59 [46∙5] NA
2 1 [7∙1] 14 [21∙9] 20 [29∙0] 34 [26∙8] NA
3 3 [21∙4] 11 [17∙2] 14 [20∙3] 14 [11∙0] NA
4-5 2 [14∙3] 14 [21∙9] 8 [11∙6] 15 [11∙8] NA
6-10 1 [7∙1] 13 [20∙3] 9 [13∙0] 4 [3∙2] NA
>10 0 [0] 1 [1∙6] 0 [0] 0 [0] NA
Table 1. Baseline characteristics. Abbreviations: CRC, colorectal cancer; AA, advanced adenoma, LA, large 
adenomas; SA, small adenomas; HC, healthy controls; BMI, body mass index; NA, not applicable; HGD: high 
grade dysplasia; LGD: low-grade dysplasia; AB: antibiotics. *Insufficient documentation of 2CRC,  6AA, 6LA, 
10SA; 11 HC.
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Table 2. Demographics of participants included in follow-up study
Polypectomy group (n=32) Healthy controls (n=32)
Age (mean, ±SD) 71∙0 ± 5∙9 60∙5 ± 11∙3
Gender (n females, %) 5 [15∙6] 15 [46∙9]
BMI (mean, ±SD) 26∙8 ± 4∙2 26∙3 ± 3∙4
Smoking status (n, %)
Active 6 [18∙8] 4 [12∙5]
Quit 18 [56∙3] 19 [59∙4]
Never 8 [25∙0] 9 [28∙1]
Indication for endoscopic assessment (n, %)
Positive FIT 10 [31∙3] 4 [12∙5]
Rectal blood loss 4 [12∙5] 1 [3∙1]
Change in bowel habits 2 [6∙3] 3 [9∙4]
Surveillance 5 [15∙6] 3 [9∙4]
Abdominal Pain 2 [6∙3] 11 [34∙4]
Diarrhea 3 [9∙4] 1 [3∙1]
Weight Loss 1 [3∙1] 0 [0]
Anaemia 0 [0] 2 [6∙3]
Constipation 0 [0] 2 [6∙3]
Family history CRC+ 1 [3∙1] 8 [25]
Monitoring previous diverticulitis/abscess 0 [0] 2 [6∙3]
Other 4 [12∙5] 5 [15∙7]
ABx 3 months prior to inclusion 2 [6∙3] 6 [18∙8]
ABx 3 months prior to second sample 1 [3∙1] 3 [9∙4]
Size adenoma (mean, ±SD) 1∙1 ± 0∙5 NA
Localization of adenoma (n, %)
Caecum 3 [9∙4] NA
Colon Ascendens 6 [18∙8] NA
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Flexura Hepatica 0 [0] NA
Colon Transversum 2 [6∙3] NA
Flexura Lienalis 1 [3∙1] NA
Colon Descendens 2 [6∙3] NA
Sigmoid 11 [34∙4] NA
Rectosigmoid 1 [3∙1] NA
Rectum 4 [12∙5] NA
Ileocecal valve 1 [3∙1] NA
Adenoma characteristics (largest adenoma) (n, [%])
≥ 10 mm 13 [40∙6] NA
Villous histology 9 [28∙1] NA
HGD 0 [0] NA
No dysplasia 3 [9∙4] NA
Hyperplasia 0 [0] NA
LGD 29 [90∙6] NA
Sessile/serrated 3 [9∙4] NA
Total number adenomas removed (n, [%])
1 7 [21∙9] NA
2 11 [34∙4] NA
3 7 [21∙9] NA
4-5 3 [9∙4] NA
6-10 4 [12∙6] NA
Table 2. Baseline characteristics of participants in polypectomy follow-up study. Abbreviations: HC, healthy 
controls; BMI, body mass index; ABx: antibiotics. 
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Table 3. Differences between all subgroups of colorectal neoplasia, polyps and healthy 
controls based on faecal volatile organic compounds
Comparison AUC (95% CI) Sensitivity Specificity PPV NPV P-value
Colorectal cancer vs healthy controls 0∙961 (0∙891-1) 1 1 0∙889 1 <0∙001
Advanced adenoma vs healthy controls 0∙964 (0∙932-0∙996) 0∙969 0∙938 0∙939 0∙968 <0∙001
Large adenomas vs healthy controls 0∙957 (0∙923-0∙992) 0∙985 0∙912 0∙918 0∙984 <0∙001
Small adenomas vs healthy controls 0∙964 (0∙940-0∙987) 0∙960 0∙929 0∙931 0∙959 <0∙001
Colorectal cancer vs advanced adenomas 0∙541 (0∙382-0∙700) 0∙984 0∙188 0∙829 0∙75 0∙294
Colorectal cancer vs large adenomas 0∙41 (0∙31 - 0∙51) 0∙06 0∙96 0∙25 0∙81 0∙920 
Colorectal cancer vs small adenomas 0∙413 (0∙379-0∙446) 1 0 0∙113 NA 0∙965
Advanced adenomas vs large adenomas 0∙53 (0∙43 - 0∙63) 0∙75 0∙36 0∙55 0∙58 0∙278
Advanced adenomas vs small adenomas 0∙578 (0∙495-0∙662) 0∙719 0∙444 0∙397 0∙757 0∙039
T0 Healthy controls vs T0 pre-polypectomy 0∙982 (0∙946-1) 1 0∙967 0∙970 1 <0∙001
T1 Healthy controls vs T1 post-polypectomy 0∙548 (0∙404-0∙691) 0∙906 0∙25 0∙547 0∙828 0∙256
T0 vs T1 pre- and post-polypectomy 0∙936 (0∙875-0∙996) 0∙906 0∙906 0∙906 0∙906 <0∙001
T0 vs T1 Healthy controls 0∙581 (0∙436-0∙726) 0∙938 0∙267 0∙577 0∙8 0∙139
Table 3. Outcomes obtained using Random Forest analyses based on 20 most discriminating features. 
Abbreviations: AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative 
predictive value; CRC, colorectal cancer; AA advanced adenoma; LA, large adenomas; SA, small adenomas; LGD, 
low-grade dysplasia; HC healthy controls.
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Figure 1. Gas Chromatography Ion Mobility Spectrometry
Figure 1. Samples are heated to 80°C for 8 minutes prior to analyses. Headspace of sample is injected into GC-
IMS. VOCs enter the GC column where they are separated based on their interaction with carrier gas. VOCs 
with similar retention times enter the IMS column simultaneously and are ionized using a soft-chemical 
ionization. Ionized VOCs travel against flow of inert gas. Drift time of VOCs is determined by ion’s mass and 
geometrical structure. The resulting ion current is measured by electrometer as function of time. 
Figure 2. Receiver operator characteristic curves for the comparison between colorectal 
cancer, advanced adenoma, large adenoma and small adenoma and healthy controls
Figure 2. Receiver operator characteristics curves. Abbreviations: CRC, colorectal cancer; AA, advanced 
adenomas; LA, large adenoma; SA, small adenoma; HC, healthy controls; AUC, area under the curve.
Figure 3. Receiver operator characteristic curves for the polypectomy follow-up 
Figure 3. Receiver operator characteristics curves. Abbreviations: AUC, area under the curve; HC, healthy 
controls.
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Figure 1. Samples are heated to 80°C for 8 minutes prior to analyses. Headspace of sample is injected into 
GC-IMS. VOCs enter the GC column where they are separated based on their interaction with carrier gas. 
VOCs with similar retention times enter the IMS column simultaneously and are ionized using a soft-
chemical ionization. Ionized VOCs travel against flow of inert gas. Drift time of VOCs is determined by ion’s 
mass and geometrical structure. The resulting ion current is measured by electrometer as function of time. 
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Figure 2. Receiver operator characteristic curves for the comparison between colorectal cancer, advanced 
adenoma, large adenoma and small adenoma and healthy controls 
Figure 2. Receiver operator characteristics curves. Abbreviations: CRC, colorectal cancer; AA, advanced 
adenomas; LA, large adenoma; SA, small adenoma; HC, healthy controls; AUC, area under the curve. 
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Figure 3. Receiver operator characteristic curves for the polypectomy follow-up 
Figure 3. Receiver operator characteristics curves. Abbreviations: AUC, area under the curve; HC, healthy 
controls. 
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Supplemental Table 1. Overview of the data generated using all five classifiers based on the 20 most 
discriminative features
Classifier AUC (95% CI) Sensitivity Specificity PPV NPV p-value 
CRC versus HC
Sparse logistic regression 0∙949 (0∙863-1) 1 1 0∙889 1 <0∙001
RandomForest 0∙961 (0∙891-1) 1 1 0∙889 1 <0∙001
GaussianProcess 0∙938 (0∙836-1) 1 1 0∙842 1 <0∙001
SupportVectorMachine 0∙945 (0∙851-1) 1 1 0∙889 1 <0∙001
NeuralNet 0∙906 (0∙775-1) 1 1 0∙889 1 <0∙001
AA versus HC
Sparse logistic regression 0∙927 (0∙869-0∙985) 0∙969 0∙906 0∙912 0∙967 <0∙001
RandomForest 0∙964 (0∙932-0∙996) 0∙969 0∙938 0∙939 0∙968 <0∙001
GaussianProcess 0∙949 (0∙902-0∙996) 0∙953 0∙938 0∙938 0∙952 <0∙001
SupportVectorMachine 0∙953 (0∙907-1) 0∙984 0∙922 0∙926 0∙983 <0∙001
NeuralNet 0∙949 (0∙901-0∙998) 1 0∙906 0∙914 1 <0∙001
Large non-AA polyps (0∙5-1∙0 cm) versus HC
Sparse logistic regression 0∙947 (0∙903-0∙991) 0∙971 0∙926 0∙930 0∙970 <0∙001
RandomForest 0∙957 (0∙923-0∙992) 0∙985 0∙912 0∙918 0∙984 <0∙001
GaussianProcess 0∙953 (0∙912-0∙994) 0∙985 0∙912 0∙918 0∙984 <0∙001
SupportVectorMachine 0∙936 (0∙886-0∙987) 0∙985 0∙912 0∙918 0∙984 <0∙001
NeuralNet 0∙955 (0∙917-0∙992) 0∙985 0∙990 0∙905 0∙984 <0∙001
Small non-AA polyps (0∙1-0∙5 cm) versus HC
Sparse logistic regression 0∙929 (0∙890-0∙969) 0∙976 0∙905 0∙911 0∙974 <0∙001
RandomForest 0∙964 (0∙940-0∙987) 0∙960 0∙929 0∙931 0∙959 <0∙001
GaussianProcess 0∙949 (0∙916-0∙982) 1 0∙889 0∙9 1 <0∙001
SupportVectorMachine 0∙944 (0∙909-0∙979) 0∙968 0∙921 0∙924 0∙967 <0∙001
NeuralNet 0∙934 (0∙895-0∙972) 0∙984 0∙905 0∙912 0∙983 <0∙001
CRC versus AA
Sparse logistic regression 0∙616 (0∙465-0∙768) 0∙531 0∙75 0∙895 0∙286 0∙077
RandomForest 0∙541 (0∙382-0∙700) 0∙984 0∙188 0∙829 0∙75 0∙294
GaussianProcess 0∙438 (0∙273-0∙604) 0∙936 0∙125 0∙811 0∙333 0∙226
SupportVectorMachine 0∙444 (0∙275-0∙613) 0∙875 0∙188 0∙812 0∙273 0∙756
NeuralNet 0∙604 (0∙465-0∙742) 0∙516 0∙75 0∙892 0∙279 0∙102
CRC versus Large non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙46 (0∙31 - 0∙61) 0∙81 0∙24 0∙2 0∙84 0∙704 
RandomForest 0∙41 (0∙31 - 0∙51) 0∙06 0∙96 0∙25 0∙81 0∙920 
GaussianProcess 0∙59 (0∙44 - 0∙74) 0∙94 0∙28 0∙23 0∙95 0∙865 
SupportVectorMachine 0∙67 (0∙53 - 0∙80) 0∙81 0∙54 0∙30 0∙93 0∙981 
NeuralNet 0∙59 (0∙44 - 0∙74) 0∙94 0∙26 0∙23 0∙95 0∙857 
CRC versus Small non-AA polyps (0∙1-0∙5 cm)
Sparse logistic regression 0∙647 (0∙540-0∙753) 1 0∙373 0∙168 1 0∙972
RandomForest 0∙413 (0∙379-0∙446) 1 0 0∙113 NA 0∙965
GaussianProcess 0∙640 (0∙516-0∙764) 1 0∙278 0∙150 1 0∙966
SupportVectorMachine 0∙618 (0∙490-0∙746) 0∙938 0∙349 0∙155 0∙978 0∙939
NeuralNet 0∙652 (0∙554-0∙770) 0∙875 0∙476 0∙175 0∙968 0∙973
AA versus Large non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙51 (0∙41 - 0∙61) 0∙79 0∙33 0∙56 0∙6 0∙397
RandomForest 0∙53 (0∙43 - 0∙63) 0∙75 0∙36 0∙55 0∙58 0∙278
GaussianProcess 0∙52 (0∙42 - 0∙62) 0∙90 0∙22 0∙55 0∙67 0∙323
SupportVectorMachine 0∙52 (0∙42 - 0∙62) 0∙54 0∙56 0∙57 0∙54 0∙338
NeuralNet 0∙47 (0∙37 - 0∙57) 0∙56 0∙5 0∙54 0∙52 0∙729
AA versus Small non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙558 (0∙471-0∙644) 0∙391 0∙722 0∙412 0∙7 0∙098
RandomForest 0∙578 (0∙495-0∙662) 0∙719 0∙444 0∙397 0∙757 0∙039
GaussianProcess 0∙554 (0∙468-0∙640) 0∙672 0∙484 0∙398 0∙744 0∙114
SupportVectorMachine 0∙527 (0∙437-0∙616) 0∙313 0∙778 0∙417 0∙690 0∙276
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NeuralNet 0∙554 (0∙467-0∙641) 0∙703 0∙460 0∙398 0∙753 0∙112
T0 Healthy versus T0 Polyp
Sparse logistic regression 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
RandomForest 0∙982 (0∙946-1) 1 0∙967 0∙970 1 <0∙001
GaussianProcess 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
SupportVectorMachine 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
NeuralNet 0∙966 (0∙904-1) 0∙969 0∙967 0∙969 0∙967 <0∙001
T1 Healthy versus T1 Polyp
Sparse logistic regression 0∙581 (0∙438-0∙723) 0∙281 0∙968 0∙818 0∙566 0∙135
RandomForest 0∙548 (0∙404-0∙691) 0∙906 0∙25 0∙547 0∙828 0∙256
GaussianProcess 0∙547 (0∙401-0∙693) 0∙25 0∙969 0∙889 0∙564 0∙259
SupportVectorMachine 0∙487 (0∙342-0∙632) 0∙656 0∙438 0∙538 0∙56 0∙575
NeuralNet 0∙667 (0∙530-0∙804) 0∙469 0∙906 0∙833 0∙630 0∙011
T0 Polyp versus T1 Polyp 
Sparse logistic regression 0∙944 (0∙889-0∙998) 0∙906 0∙875 0∙879 0∙903 <0∙001
RandomForest 0∙936 (0∙875-0∙996) 0∙906 0∙906 0∙906 0∙906 <0∙001
GaussianProcess 0∙932 (0∙866-0∙998) 0∙906 0∙875 0∙879 0∙903 <0∙001
SupportVectorMachine 0∙898 (0∙811-0∙985) 0∙875 0∙906 0∙903 0∙879 <0∙001
NeuralNet 0∙951 (0∙889-1) 0∙906 0∙969 0∙967 0∙912 <0∙001
T0 Healthy versus T1 Healthy
Sparse logistic regression 0∙634 (0∙495-0∙774) 0∙531 0∙733 0∙68 0∙595 0∙035
RandomForest 0∙581 (0∙436-0∙726) 0∙938 0∙267 0∙577 0∙8 0∙139
GaussianProcess 0∙534 (0∙387-0∙681) 0∙938 0∙233 0∙566 0∙778 0∙324
SupportVectorMachine 0∙474 (0∙326-0∙622) 0∙531 0∙567 0∙567 0∙531 0∙365
NeuralNet 0∙627 (0∙486-0∙769) 0∙406 0∙867 0∙765 0∙578 0∙043
Supplemental Table 1. Overview of the data generated using all five classifiers based on the 20 most discriminative features. Abbreviations: 
CRC, colorectal cancer; AA, advanced adenomas; LGD, low grade dysplasia; HC, healthy controls; AUC, area under the curve; PPV, positive 
predictive value; NPV, negative predictive value.
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Supplemental Table 2. Overview of the data generated using all five classifiers based on the 50 most 
discriminative features
Classifier AUC (95% CI) Sensitivity Specificity PPV NPV p-value 
CRC versus HC
Sparse logistic regression 0∙965 (0∙901-1) 1 0∙875 0∙889 1 <0∙001
RandomForest 0∙989 (0∙965-1) 1 0∙875 0∙889 1 <0∙001
GaussianProcess 0∙965 (0∙906-1) 1 0∙875 0∙889 1 <0∙001
SupportVectorMachine 0∙984 (0∙955-1) 1 0∙875 0∙889 1 <0∙001
NeuralNet 0∙930 (0∙823-1) 0∙938 0∙938 0∙938 0∙938 <0∙001
AA versus HC
Sparse logistic regression 0∙908 (0∙849-0∙967) 0∙969 0∙860 0∙873 0∙965 <0∙001
RandomForest 0∙959 (0∙923-0∙994) 0∙953 0∙938 0∙938 0∙952 <0∙001
GaussianProcess 0∙947 (0∙9-0∙995) 0∙953 0∙938 0∙938 0∙952 <0∙001
SupportVectorMachine 0∙941 (0∙889-0∙993) 0∙953 0∙938 0∙938 0∙952 <0∙001
NeuralNet 0∙920 (0∙861-0∙979) 0∙953 0∙938 0∙938 0∙952 <0∙001
Large non-AA polyps (0∙5-1∙0 cm) versus HC
Sparse logistic regression 0∙956 (0∙915-0∙996) 0∙985 0∙926 0∙931 0∙984 <0∙001
RandomForest 0∙970 (0∙942-0∙999) 0∙985 0∙912 0∙918 0∙984 <0∙001
GaussianProcess 0∙964 (0∙929-1) 0∙970 0∙941 0∙943 0∙970 <0∙001
SupportVectorMachine 0∙956 (0∙913-0∙998) 0∙985 0∙926 0∙931 0∙984 <0∙001
NeuralNet 0∙938 (0∙888-0∙988) 0∙985 0∙912 0∙918 0∙984 <0∙001
Small non-AA polyps (0∙1-0∙5 cm) versus HC
Sparse logistic regression 0∙944 (0∙909-0∙980) 1 0∙897 0∙906 1 <0∙001
RandomForest 0∙970 (0∙949-0∙991) 1 0∙889 0∙9 1 <0∙001
GaussianProcess 0∙956 (0∙925-0∙987) 0∙984 0∙913 0∙919 0∙983 <0∙001
SupportVectorMachine 0∙951 (0∙918-0∙984) 0∙968 0∙929 0∙931 0∙967 <0∙001
NeuralNet 0∙939 (0∙903-0∙975) 0∙984 0∙913 0∙919 0∙983 <0∙001
CRC versus AA
Sparse logistic regression 0∙608 (0∙469-0∙748) 0∙406 0∙875 0∙929 0∙270 0∙916
RandomForest 0∙536 (0∙378-0∙693) 1 0∙188 0∙831 1 0∙319
GaussianProcess 0∙477 (0∙313-0∙640) 0∙969 0∙125 0∙816 0∙5 0∙389
SupportVectorMachine 0∙587 (0∙414-0∙760) 0∙906 0∙313 0∙841 0∙455 0∙560
NeuralNet 0∙541 (0∙378-0∙704) 0∙406 0∙75 0∙867 0∙24 0∙309
CRC versus Large non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙520 (0∙364-0∙677) 0∙438 0∙647 0∙226 0∙830 0∙601
RandomForest 0∙432 (0∙321-0∙544) 0∙063 0∙971 0∙333 0∙815 0∙855
GaussianProcess 0∙546 (0∙398-0∙694) 0∙875 0∙309 0∙230 0∙913 0∙718
SupportVectorMachine 0∙582 (0∙419-0∙745) 0∙563 0∙603 0∙25 0∙854 0∙846
NeuralNet 0∙521 (0∙372-0∙670) 0∙875 0∙265 0∙219 0∙9 0∙604
CRC versus Small non-AA polyps (0∙1-0∙5 cm)
Sparse logistic regression 0∙670 (0∙548-0∙792) 0∙938 0∙484 0∙188 0∙984 0∙987
RandomForest 0∙400 (0∙328-0∙472) 1 0 0∙113 NA 0∙959
GaussianProcess 0∙578 (0∙444-0∙712) 0∙938 0∙349 0∙155 0∙978 0∙847
SupportVectorMachine 0∙429 (0∙282-0∙575) 0∙625 0∙421 0∙120 0∙898 0∙824
NeuralNet 0∙476 (0∙345-0∙607) 0∙938 0∙206 0∙130 0∙963 0∙622
AA versus Large non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙54 (0∙44 - 0∙64) 0∙85 0∙30 0∙56 0∙66 0∙202 
RandomForest 0∙57 (0∙48 - 0∙67) 0∙76 0∙42 0∙58 0∙63 0∙072 
GaussianProcess 0∙58 (0∙49 - 0∙68) 0∙34 0∙80 0∙64 0∙53 0∙050 
SupportVectorMachine 0∙58 (0∙49 - 0∙68) 0∙60 0∙58 0∙60 0∙58 0∙047 
NeuralNet 0∙55 (0∙45 - 0∙65) 0∙72 0∙42 0∙57 0∙59 0∙167 
T0 Healthy versus T0 Polyp
Sparse logistic regression 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
RandomForest 0∙981 (0∙943-1) 1 0∙967 0∙970 1 <0∙001
GaussianProcess 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
SupportVectorMachine 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
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NeuralNet 0∙945 (0∙869-1) 0∙969 0∙967 0∙969 0∙967 <0∙001
T1 Healthy versus T1 Polyp
Sparse logistic regression 0∙566 (0∙420-0∙706) 0∙875 0∙406 0∙596 0∙765 0∙182
RandomForest 0∙562 (0∙418-0∙706) 0∙906 0∙281 0∙558 0∙75 0∙200
GaussianProcess 0∙533 (0∙389-0∙678) 0∙688 0∙469 0∙564 0∙6 0∙326
SupportVectorMachine 0∙606 (0∙463-0∙750) 0∙813 0∙5 0∙619 0∙727 0∙072
NeuralNet 0∙579 (0∙435-0∙722) 0∙75 0∙531 0∙615 0∙68 0∙141
T0 Polyp versus T1 Polyp 
Sparse logistic regression 0∙961 (0∙917-1) 0∙938 0∙906 0∙910 0∙935 <0∙001
RandomForest 0∙967 (0∙924-1) 0∙969 0∙875 0∙886 0∙966 <0∙001
GaussianProcess 0∙958 (0∙902-1) 0∙969 0∙906 0∙912 0∙967 <0∙001
SupportVectorMachine 0∙926 (0∙844-1) 0∙938 0∙938 0∙938 0∙938 <0∙001
NeuralNet 0∙964 (0∙905-1) 0∙938 0∙969 0∙968 0∙940 <0∙001
T0 Healthy versus T1 Healthy
Sparse logistic regression 0∙756 (0∙635-0∙878) 0∙469 0∙967 0∙938 0∙630 0∙000
RandomForest 0∙680 (0∙546-0∙815) 0∙563 0∙733 0∙692 0∙611 0∙008
GaussianProcess 0∙599 (0∙456-0∙742) 0∙688 0∙567 0∙629 0∙630 0∙092
SupportVectorMachine 0∙621 (0∙480-0∙762) 0∙406 0∙867 0∙765 0∙578 0∙052
NeuralNet 0∙725 (0∙591-0∙860) 0∙719 0∙833 0∙821 0∙735 0∙001
Supplemental Table 3. Overview of the data generated using all five classifiers based on the 50 most discriminative features. 
Abbreviations: CRC, colorectal cancer; AA, advanced adenomas; LGD, low grade dysplasia; HC, healthy controls; AUC, area under 
the curve; PPV, positive predictive value; NPV, negative predictive value.
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Supplemental Table 3. Overview of the data generated using all five classifiers based on the 100 most 
discriminative features
Classifier AUC (95% CI) Sensitivity Specificity PPV NPV p-value 
CRC versus HC
Sparse logistic regression 0∙973 (927-1) 1 0∙875 0∙889 1 <0∙001
RandomForest 0∙988 (0∙965-1) 1 0∙875 0∙889 1 <0∙001
GaussianProcess 0∙965 (0∙910-1) 1 0∙875 0∙889 1 <0∙001
SupportVectorMachine 0∙992 (0∙974-1) 1 0∙938 0∙941 1 <0∙001
NeuralNet 1 (1-1) 1 1 1 1 <0∙001
AA versus HC
Sparse logistic regression 0∙929 (0∙875-0∙984) 0∙984 0∙875 0∙887 0∙982 <0∙001
RandomForest 0∙956 (0∙917-0∙994) 0∙953 0∙938 0∙938 0∙952 <0∙001
GaussianProcess 0∙941 (0∙889-0∙993) 0∙953 0∙938 0∙938 0∙952 <0∙001
SupportVectorMachine 0∙939 (0∙887-0∙992) 0∙953 0∙938 0∙938 0∙952 <0∙001
NeuralNet 0∙915 (0∙853-0∙977) 0∙953 0∙938 0∙938 0∙952 <0∙001
Large non-AA polyps (0∙5-1∙0 cm) versus HC
Sparse logistic regression 0∙925 (0∙870-0∙980) 0∙985 0∙912 0∙918 0∙984 <0∙001
RandomForest 0∙961 (0∙926-0∙995) 0∙985 0∙912 0∙918 0∙984 <0∙001
GaussianProcess 0∙958 (0∙916-1) 0∙985 0∙941 0∙944 0∙985 <0∙001
SupportVectorMachine 0∙939 (0∙887-0∙992) 0∙985 0∙941 0∙944 0∙985 <0∙001
NeuralNet 0∙950 (0∙904-0∙995) 0∙985 0∙926 0∙931 0∙984 <0∙001
Small non-AA polyps (0∙1-0∙5 cm) versus HC
Sparse logistic regression 0∙954 (0∙921-0∙987) 0∙984 0∙913 0∙919 0∙983 <0∙001
RandomForest 0∙973 (0∙953-0∙994) 0∙952 0∙952 0∙952 0∙952 <0∙001
GaussianProcess 0∙964 (0∙935-0∙992) 0∙913 0∙920 1 <0∙001
SupportVectorMachine 0∙961 (0∙931-0∙991) 0∙976 0∙944 0∙946 0∙975 <0∙001
NeuralNet 0∙944 (0∙908-0∙979) 0∙984 0∙929 0∙932 0∙983 <0∙001
CRC versus AA
Sparse logistic regression 0∙583 (0∙417-0∙750) 0∙484 0∙688 0∙861 0∙25 0∙153
RandomForest 0∙577 (0∙420-0∙734) 0∙578 0∙625 0∙860 0∙270 0∙167
GaussianProcess 0∙480 (0∙321-0∙640) 0∙875 0∙188 0∙812 0∙272 0∙407
SupportVectorMachine 0∙497 (0∙323-0∙671) 0∙875 0∙25 0∙824 0∙333 0∙517
NeuralNet 0∙614 (0∙453-0∙775) 0∙625 0∙688 0∙888 0∙314 0∙081
CRC versus Large non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙495 (0∙333-0∙656) 0∙438 0∙647 0∙226 0∙830 0∙530
RandomForest 0∙447 (0∙329-0∙564) 0∙063 0∙985 0∙5 0∙817 0∙792
GaussianProcess 0∙545 (0∙393-0∙697) 0∙938 0∙221 0∙221 0∙938 0∙714
SupportVectorMachine 0∙576 (0∙410-0∙742) 0∙313 0∙824 0∙294 0∙836 0∙830
NeuralNet 0∙460 (0∙303-0∙617) 0∙5 0∙574 0∙216 0∙830 0∙692
CRC versus Small non-AA polyps (0∙1-0∙5 cm)
Sparse logistic regression 0∙667 (0∙527-0∙808) 0∙688 0∙667 0∙208 0∙944 0∙986
RandomForest 0∙435 (0∙324-0∙545) 0∙188 0∙825 0∙12 0∙889 0∙852
GaussianProcess 0∙460 (0∙318-0∙601) 0∙875 0∙198 0∙122 0∙926 0∙704
SupportVectorMachine 0∙560 (0∙386-0∙834) 0∙5 0∙683 0∙167 0∙915 0∙783
NeuralNet 0∙497 (0∙340-0∙655) 0∙563 0∙587 0∙148 0∙914 0∙515
AA versus Large non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙457 (0∙309-0∙605) 0∙813 0∙235 0∙2 0∙842 0∙704
RandomForest 0∙413 (0∙313-0∙513) 0∙063 0∙956 0∙25 0∙813 0∙920
GaussianProcess 0∙588 (0∙441-0∙736) 0∙938 0∙279 0∙234 0∙95 0∙865
SupportVectorMachine 0∙666 (0∙533-0∙800) 0∙813 0∙544 0∙295 0∙925 0∙981
NeuralNet 0∙585 (0∙435-0∙736) 0∙938 0∙265 0∙231 0∙947 0∙857
AA versus Small non-AA polyps (0∙5-1∙0 cm)
Sparse logistic regression 0∙613 (0∙531-0∙694) 0∙800 0∙452 0∙425 0∙814 0∙006
RandomForest 0∙566 (0∙472-0∙659) 0∙328 0∙841 0∙512 0∙711 0∙070
GaussianProcess 0∙606 (0∙522-0∙689) 0∙719 0∙492 0∙418 0∙775 0∙009
SupportVectorMachine 0∙566 (0∙479-0∙653) 0∙438 0∙698 0∙424 0∙710 0∙068
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NeuralNet 0∙541 (0∙455-0∙626) 0∙578 0∙595 0∙420 0∙735 0∙181
T0 Healthy versus T0 Polyp
Sparse logistic regression 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
RandomForest 0∙979 (0∙938-1) 1 0∙967 0∙970 1 <0∙001
GaussianProcess 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
SupportVectorMachine 0∙969 (0∙907-1) 1 0∙967 0∙970 1 <0∙001
NeuralNet 0∙949 (0∙877-1) 0∙969 0∙967 0∙969 0∙967 <0∙001
T1 Healthy versus T1 Polyp
Sparse logistic regression 0∙560 (0∙415-0∙704) 0∙875 0∙313 0∙56 0∙714 0∙208
RandomForest 0∙547 (0∙403-0∙692) 0∙906 0∙25 0∙547 0∙727 0∙260
GaussianProcess 0∙559 (0∙415-0∙703) 0∙719 0∙469 0∙575 0∙625 0∙210
SupportVectorMachine 0∙588 (0∙444-0∙733) 0∙813 0∙469 0∙605 0∙714 0∙113
NeuralNet 0∙551 (0∙406-0∙697) 0∙563 0∙626 0∙621 0∙6 0∙243
T0 Polyp versus T1 Polyp 
Sparse logistic regression 0∙983 (0∙959-1) 1 0∙906 0∙914 1 <0∙001
RandomForest 0∙982 (0∙959-1) 1 0∙844 0∙865 1 <0∙001
GaussianProcess 0∙979 (0∙951-1) 1 0∙875 0∙889 1 <0∙001
SupportVectorMachine 0∙937 (0∙854-1) 0∙969 0∙906 0∙812 0∙967 <0∙001
NeuralNet 0∙989 (0∙969-1) 0∙969 0∙969 0∙969 0∙969 <0∙001
T0 Healthy versus T1 Healthy
Sparse logistic regression 0∙804 (0∙690-0∙918) 0∙719 0∙9 0∙885 0∙75 <0∙001
RandomForest 0∙851 (0∙627-0∙874) 0∙594 0∙867 0∙826 0∙667 <0∙001
GaussianProcess 0∙707 (0∙573-0∙838) 0∙531 0∙833 0∙773 0∙625 0∙002
SupportVectorMachine 0∙668 (0∙532-0∙803) 0∙594 0∙733 0∙704 0∙629 0∙002
NeuralNet 0∙773 (0∙651-0∙894) 0∙594 0∙933 0∙905 0∙683 <0∙001
Supplemental Table 3. Overview of the data generated using all five classifiers based on the 100 most discriminative features. 
Abbreviations: CRC, colorectal cancer; AA, advanced adenomas; LGD, low grade dysplasia; HC, healthy controls; AUC, area under 
the curve; PPV, positive predictive value; NPV, negative predictive value.
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